BIOPHARMA CREDIT PLC

Declaration of Voting Results & Voting Rights Announcements • Jun 25, 2020

National Storage Mechanism | Additional information

RNS Number : 1242R

BioPharma Credit PLC

25 June 2020

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions were passed on a show of hands.

The proxy votes received in relation to these resolutions were as follows:

Resolutions	Votes For	%	Votes Against	%	Votes at Chairman's Discretion	Votes Withheld
1: To receive and accept the annual report and financial statements	696,146,375	100	0	0	0	0
2: To approve the Directors' Remuneration Report	695,907,982	99.97	227,208	0.03	0	11,185
3: To re-elect Jeremy Sillem as a Director	696,141,190	100	0	0	0	5,185
4: To re-elect Colin Bond as a Director	696,141,190	100	0	0	0	5,185
5: To re-elect Duncan Budge as a Director	696,141,190	100	0	0	0	5,185
6: To re-elect Harry Hyman as a Director	696,141,190	100	0	0	0	5,185
7: To re-elect Stephanie Léouzon as a Director	696,141,190	100	0	0	0	5,185
8: To re-appoint Pricewaterhouse Coopers LLP as Auditor to the Company	695,908,232	99.97	226,958	0.03	0	11,185
9: To authorise the Directors to determine the remuneration of the Auditor	695,914,232	99.97	226,958	0.03	0	5,185
10: To approve the Company's dividend payment policy	696,146,375	100	0	0	0	0
11: To authorise the Company to make market purchases of ordinary shares	695,913,982	99.97	227,208	0.03	0	5,185
12: To authorise the Company to hold general meetings on 14 clear days' notice	696,140,940	99.99	250	0.01	0	5,185

A copy of resolutions 11 and 12 has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

25 June 2020

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

Buchanan

+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGSEDFDIESSEIM